E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006007 |
E.1.2 | Term | Bone sarcoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether glucarpidase rescue after high-dose methotrexate reduces delay to subsequent cycle of chemotherapy due to methotrexate toxicity |
|
E.2.2 | Secondary objectives of the trial |
1.To investigate whether glucarpidase rescue after high-dose methotrexate reduces the incidence, severity and duration of methotrexate associated adverse effects 2.To study the pharmacokinetics of methotrexate and 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) after glucarpidase administration 3.To evaluate any adverse effects associated with the use of glucarpidase 4.To investigate the economic impact of using glucarpidase versus standard rescue 5.To investigate the effect of glucarpidase on the quality of life of patients treated with high dose methotrexate 6.To assess the anti-glucarpidase antibody response
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Written informed consent of patient or parent/guardian
Diagnosis of high grade osteosarcoma, localised or metastatic or high grade osteosarcoma as a second maligancy or spindle cell sarcoma of bone or relapsed high grade osteosarcoma
Age: 5-50 years at registration
Patients able to comply with study and follow up procedures (WHO performance scale 0-2)
No concomitant anti-cancer or investigational drugs during the study and complete resolution of toxicity related to previous treatment
Life expectancy of at least 3 months
Haematopoietic function: Absolute neutrophil count ≥1 x109/L, Platelets ≥75 x109/L
Hepatic function: Bilirubin ≤1.5 x ULN,
Renal function: Glomerular Filtration Rate (radioisotope) ≥ 70 ml/min/1.73m2
|
|
E.4 | Principal exclusion criteria |
Patients who previously received glucarpidase
Pregnant or breast feeding women (patients with reproductive potential of either gender must use contraception, as described in section 5.2 of the protocol)
Concomitant treatment with agents which interact with methotrexate metabolism or excretion
Serous effusions including ascites and pleural effusions
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Assessment of fitness to receive chemotherapy on day 15 of each cycle (fitness criteria described in section 8 of the protocol) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
day-7-0, day 1, day 2, day 8, Day 9, Day 15, day 22, day 23, day 29, day 30, day 36, |
|
E.5.2 | Secondary end point(s) |
1. Incidence of methotrexate-associated toxicity (CTCAE v3.0 grade ≥2) 2. Serum methotrexate and DAMPA concentrations 3. Anti-glucarpidase IgG antibody response and neutralisation of glucarpidase activity 4. Number of days required in hospital per cycle and total dose of folinic acid required per cycle 5.Quality of life assessment (QLQ-C30 version 3, FACT-G and PedsQL 3.0 cancer module acute version)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
day-7-0, day 1, day 2, day 8, Day 9, Day 15, day 22, day 23, day 29, day 30, day 36, Day 51, day 111, day 201 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The duration of treatment for each patient is 6 weeks (allowing for recovery after the last methotrexate course). However, patients will be followed up on day 30 and at 3 and 6 months after starting their second chemotherapy cycle to investigate anti-glucarpidase response. The trial will be completed after all 38 participants are recruited, treated and followed up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |